November: Signed a license-out agreement for second-generation anemia biosimilar drug,
Darbepoetin alfa (DA-3880)with Polifarma in Turkey, covering Turkey, Brazil, and Mexico.

August: Entered a license-out agreement for multi-drug-resistant Gram-negative bacterial antibiotic, DA-7310,
with Yangtze River Pharmaceutical Group in China, covering China, Hong Kong, and Macau

July: a global license-out agreement (excluding Korea, Japan, and some Asian markets) for the biosimilar to Stelara,
DMB-3115, with multinational company Intas Pharmaceuticals

March: Relocated the Biotech Research Center to Songdo, Incheon

December: Recognized as a 2020 Family-Friendly Certified company, reflecting our employee-centric culture

December: Our growth hormone product, Grotropin, surpassed KRW 30 billion in annual sales

December: Launched Sugamet XR Tab. 5/1,000mg, expanding our diabetes treatment portfolio.

November: Signed an agreement with China's Hansoh Pharma to introduce a groundbreaking immuno-oncology drug

November: Hosted a Peace Forest Reforestation ceremony, symbolizing our dedication to social responsibility

October: Jublia, our nail fungus treatment, achieved over KRW 50 billion in cumulative sales

June: Passed the ISO 37001 anti-bribery management system for the second consecutive year, highlighting our ethical business practices

June: Established the Social Value Committee, demonstrating our commitment to sustainable management

June: Signed an agreement with the Korea Medical Assistance Foundation to provide medication support for low-income cancer patients

May: Results of Suganon EVERGREEN Study published in a prestigious SCI-level international journal

March: Successfully launched diabetes treatment Suganon in the Russian market